The relationship looks reasonable since some critical mutations which deciding AML risk classification closely related with the neoplasm clone evolution (such as BCR-ABL1 fusion, complex karyotye) and cell apoptosis abnormality (such as TP53 mutaiton). This evidence concerns the gene TP53 and acute myeloid leukemia.